These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28376812)

  • 1. Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice.
    Versiani AF; Astigarraga RG; Rocha ES; Barboza AP; Kroon EG; Rachid MA; Souza DG; Ladeira LO; Barbosa-Stancioli EF; Jorio A; Da Fonseca FG
    J Nanobiotechnology; 2017 Apr; 15(1):26. PubMed ID: 28376812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice.
    Chiang CY; Liu SJ; Hsieh CH; Chen MY; Tsai JP; Liu HH; Chen IH; Chong P; Leng CH; Chen HW
    Vaccine; 2016 Feb; 34(8):1054-61. PubMed ID: 26776472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
    Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
    Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
    Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
    Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
    De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
    Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
    Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
    Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.
    Zhao H; Jiang T; Zhou XZ; Deng YQ; Li XF; Chen SP; Zhu SY; Zhou X; Qin ED; Qin CF
    PLoS One; 2014; 9(1):e86573. PubMed ID: 24466156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement.
    Chiang CY; Pan CH; Hsieh CH; Tsai JP; Chen MY; Liu HH; Liu SJ; Chong P; Leng CH; Chen HW
    PLoS Negl Trop Dis; 2013; 7(9):e2432. PubMed ID: 24069487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-walled carbon nanotubes increase antibody-producing B cells in mice immunized with a tetravalent vaccine candidate for dengue virus.
    Calegari LP; Dias RS; de Oliveira MD; Pessoa CR; de Oliveira AS; Oliveira AF; da Silva CC; Fonseca FG; Versiani AF; De Paula SO
    J Nanobiotechnology; 2016 Jul; 14(1):61. PubMed ID: 27465605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis.
    Quinan BR; Versiani AF; da Fonseca FG
    Vaccine; 2016 Dec; 34(50):6120-6122. PubMed ID: 27817963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.
    Metz SW; Tian S; Hoekstra G; Yi X; Stone M; Horvath K; Miley MJ; DeSimone J; Luft CJ; de Silva AM
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005071. PubMed ID: 27764114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.
    Chiang CY; Huang MH; Hsieh CH; Chen MY; Liu HH; Tsai JP; Li YS; Chang CY; Liu SJ; Chong P; Leng CH; Chen HW
    PLoS Negl Trop Dis; 2012; 6(5):e1645. PubMed ID: 22616020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
    Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
    Front Immunol; 2019; 10():59. PubMed ID: 30761131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.